Now showing items 2185-2204 of 3555

    • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. 

      Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, K; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Iglesias Docampo, LC; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Monga, M; Lynch, M; Geese, WJ; Kopit, J; Shaw, JW; Gillison, ML (2016-11)
      BACKGROUND:Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 ...
    • Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. 

      Ferris, RL; Licitra, L; Fayette, J; Even, C; Blumenschein, G; Harrington, KJ; Guigay, J; Vokes, EE; Saba, NF; Haddad, R; Ramkumar, S; Russell, J; Brossart, P; Tahara, M; Colevas, AD; Concha-Benavente, F; Lynch, M; Li, L; Gillison, ML
      PURPOSE:Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic ...
    • Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. 

      Haddad, R; Concha-Benavente, F; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Kasper, S; Vokes, EE; Worden, F; Saba, NF; Tahara, M; Jayaprakash, V; Lynch, M; Li, L; Gillison, ML; Harrington, KJ; Ferris, RL (2019-09)
      BACKGROUND:Response patterns with immune checkpoint inhibitors may be different from those with chemotherapy. Therefore, assessment of response to immunotherapy with the Response Evaluation Criteria in Solid Tumors (RECIST), ...
    • Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. 

      Saba, NF; Blumenschein, G; Guigay, J; Licitra, L; Fayette, J; Harrington, KJ; Kiyota, N; Gillison, ML; Ferris, RL; Jayaprakash, V; Li, L; Brossart, P
      OBJECTIVES:Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. Nivolumab is ...
    • Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. 

      Harrington, KJ; Ferris, RL; Blumenschein, G; Colevas, AD; Fayette, J; Licitra, L; Kasper, S; Even, C; Vokes, EE; Worden, F; Saba, NF; Kiyota, N; Haddad, R; Tahara, M; Grünwald, V; Shaw, JW; Monga, M; Lynch, M; Taylor, F; DeRosa, M; Morrissey, L; Cocks, K; Gillison, ML; Guigay, J (2017-08)
      BACKGROUND:Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options and poor prognosis. Nivolumab significantly improved survival of this patient ...
    • Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. 

      Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, KJ; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Docampo, LCI; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Lynch, M; Jayaprakash, V; Li, L; Gillison, ML (2018-06)
      OBJECTIVES:We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory ...
    • The NMDA receptor regulates competition of epithelial cells in the Drosophila wing. 

      Banreti, AR; Meier, P (2020-05-06)
      Cell competition is an emerging principle that eliminates suboptimal or potentially dangerous cells. For 'unfit' cells to be detected, their competitive status needs to be compared to the collective fitness of cells within ...
    • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 

      Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2; Hollestelle, A; van der Baan, FH; Berchuck, A; Johnatty, SE; Aben, KK; Agnarsson, BA; Aittomäki, K; Alducci, E; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Antoniou, AC; Apicella, C; Arndt, V; Arnold, N; Arun, BK; Arver, B; Ashworth, A; Australian Ovarian Cancer Study Group; Baglietto, L; Balleine, R; Bandera, EV; Barrowdale, D; Bean, YT; Beckmann, L; Beckmann, MW; Benitez, J; Berger, A; Berger, R; Beuselinck, B; Bisogna, M; Bjorge, L; Blomqvist, C; Bogdanova, NV; Bojesen, A; Bojesen, SE; Bolla, MK; Bonanni, B; Brand, JS; Brauch, H; Breast Cancer Family Register; Brenner, H; Brinton, L; Brooks-Wilson, A; Bruinsma, F; Brunet, J; Brüning, T; Budzilowska, A; Bunker, CH; Burwinkel, B; Butzow, R; Buys, SS; Caligo, MA; Campbell, I; Carter, J; Chang-Claude, J; Chanock, SJ; Claes, KBM; Collée, JM; Cook, LS; Couch, FJ; Cox, A; Cramer, D; Cross, SS; Cunningham, JM; Cybulski, C; Czene, K; Damiola, F; Dansonka-Mieszkowska, A; Darabi, H; de la Hoya, M; deFazio, A; Dennis, J; Devilee, P; Dicks, EM; Diez, O; Doherty, JA; Domchek, SM; Dorfling, CM; Dörk, T; Silva, IDS; du Bois, A; Dumont, M; Dunning, AM; Duran, M; Easton, DF; Eccles, D; Edwards, RP; Ehrencrona, H; Ejlertsen, B; Ekici, AB; Ellis, SD; EMBRACE; Engel, C; Eriksson, M; Fasching, PA; Feliubadalo, L; Figueroa, J; Flesch-Janys, D; Fletcher, O; Fontaine, A; Fortuzzi, S; Fostira, F; Fridley, BL; Friebel, T; Friedman, E; Friel, G; Frost, D; Garber, J; García-Closas, M; Gayther, SA; GEMO Study Collaborators; GENICA Network; Gentry-Maharaj, A; Gerdes, A-M; Giles, GG; Glasspool, R; Glendon, G; Godwin, AK; Goodman, MT; Gore, M; Greene, MH; Grip, M; Gronwald, J; Gschwantler Kaulich, D; Guénel, P; Guzman, SR; Haeberle, L; Haiman, CA; Hall, P; Halverson, SL; Hamann, U; Hansen, TVO; Harter, P; Hartikainen, JM; Healey, S; HEBON; Hein, A; Heitz, F; Henderson, BE; Herzog, J; T Hildebrandt, MA; Høgdall, CK; Høgdall, E; Hogervorst, FBL; Hopper, JL; Humphreys, K; Huzarski, T; Imyanitov, EN; Isaacs, C; Jakubowska, A; Janavicius, R; Jaworska, K; Jensen, A; Jensen, UB; Johnson, N; Jukkola-Vuorinen, A; Kabisch, M; Karlan, BY; Kataja, V; Kauff, N; KConFab Investigators; Kelemen, LE; Kerin, MJ; Kiemeney, LA; Kjaer, SK; Knight, JA; Knol-Bout, JP; Konstantopoulou, I; Kosma, V-M; Krakstad, C; Kristensen, V; Kuchenbaecker, KB; Kupryjanczyk, J; Laitman, Y; Lambrechts, D; Lambrechts, S; Larson, MC; Lasa, A; Laurent-Puig, P; Lazaro, C; Le, ND; Le Marchand, L; Leminen, A; Lester, J; Levine, DA; Li, J; Liang, D; Lindblom, A; Lindor, N; Lissowska, J; Long, J; Lu, KH; Lubinski, J; Lundvall, L; Lurie, G; Mai, PL; Mannermaa, A; Margolin, S; Mariette, F; Marme, F; Martens, JWM; Massuger, LFAG; Maugard, C; Mazoyer, S; McGuffog, L; McGuire, V; McLean, C; McNeish, I; Meindl, A; Menegaux, F; Menéndez, P; Menkiszak, J; Menon, U; Mensenkamp, AR; Miller, N; Milne, RL; Modugno, F; Montagna, M; Moysich, KB; Müller, H; Mulligan, AM; Muranen, TA; Narod, SA; Nathanson, KL; Ness, RB; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, FC; Nielsen, SF; Nordestgaard, BG; Nussbaum, RL; Odunsi, K; Offit, K; Olah, E; Olopade, OI; Olson, JE; Olson, SH; Oosterwijk, JC; Orlow, I; Orr, N; Orsulic, S; Osorio, A; Ottini, L; Paul, J; Pearce, CL; Pedersen, IS; Peissel, B; Pejovic, T; Pelttari, LM; Perkins, J; Permuth-Wey, J; Peterlongo, P; Peto, J; Phelan, CM; Phillips, K-A; Piedmonte, M; Pike, MC; Platte, R; Plisiecka-Halasa, J; Poole, EM; Poppe, B; Pylkäs, K; Radice, P; Ramus, SJ; Rebbeck, TR; Reed, MWR; Rennert, G; Risch, HA; Robson, M; Rodriguez, GC; Romero, A; Rossing, MA; Rothstein, JH; Rudolph, A; Runnebaum, I; Salani, R; Salvesen, HB; Sawyer, EJ; Schildkraut, JM; Schmidt, MK; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schrauder, MG; Schumacher, F; Schwaab, I; Scuvera, G; Sellers, TA; Severi, G; Seynaeve, CM; Shah, M; Shrubsole, M; Siddiqui, N; Sieh, W; Simard, J; Singer, CF; Sinilnikova, OM; Smeets, D; Sohn, C; Soller, M; Song, H; Soucy, P; Southey, MC; Stegmaier, C; Stoppa-Lyonnet, D; Sucheston, L; SWE-BRCA; Swerdlow, A; Tangen, IL; Tea, M-K; Teixeira, MR; Terry, KL; Terry, MB; Thomassen, M; Thompson, PJ; Tihomirova, L; Tischkowitz, M; Toland, AE; Tollenaar, RAEM; Tomlinson, I; Torres, D; Truong, T; Tsimiklis, H; Tung, N; Tworoger, SS; Tyrer, JP; Vachon, CM; Van 't Veer, LJ; van Altena, AM; Van Asperen, CJ; van den Berg, D; van den Ouweland, AMW; van Doorn, HC; Van Nieuwenhuysen, E; van Rensburg, EJ; Vergote, I; Verhoef, S; Vierkant, RA; Vijai, J; Vitonis, AF; von Wachenfeldt, A; Walsh, C; Wang, Q; Wang-Gohrke, S; Wappenschmidt, B; Weischer, M; Weitzel, JN; Weltens, C; Wentzensen, N; Whittemore, AS; Wilkens, LR; Winqvist, R; Wu, AH; Wu, X; Yang, HP; Zaffaroni, D; Pilar Zamora, M; Zheng, W; Ziogas, A; Chenevix-Trench, G; Pharoah, PDP; Rookus, MA; Hooning, MJ; Goode, EL (2016-05)
      OBJECTIVE:Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer ...
    • No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. 

      Easton, DF; Lesueur, F; Decker, B; Michailidou, K; Li, J; Allen, J; Luccarini, C; Pooley, KA; Shah, M; Bolla, MK; Wang, Q; Dennis, J; Ahmad, J; Thompson, ER; Damiola, F; Pertesi, M; Voegele, C; Mebirouk, N; Robinot, N; Durand, G; Forey, N; Luben, RN; Ahmed, S; Aittomäki, K; Anton-Culver, H; Arndt, V; Australian Ovarian Cancer Study Group; Baynes, C; Beckman, MW; Benitez, J; Van Den Berg, D; Blot, WJ; Bogdanova, NV; Bojesen, SE; Brenner, H; Chang-Claude, J; Chia, KS; Choi, J-Y; Conroy, DM; Cox, A; Cross, SS; Czene, K; Darabi, H; Devilee, P; Eriksson, M; Fasching, PA; Figueroa, J; Flyger, H; Fostira, F; García-Closas, M; Giles, GG; Glendon, G; González-Neira, A; Guénel, P; Haiman, CA; Hall, P; Hart, SN; Hartman, M; Hooning, MJ; Hsiung, C-N; Ito, H; Jakubowska, A; James, PA; John, EM; Johnson, N; Jones, M; Kabisch, M; Kang, D; kConFab Investigators; Kosma, V-M; Kristensen, V; Lambrechts, D; Li, N; Lifepool Investigators; Lindblom, A; Long, J; Lophatananon, A; Lubinski, J; Mannermaa, A; Manoukian, S; Margolin, S; Matsuo, K; Meindl, A; Mitchell, G; Muir, K; NBCS Investigators; Nevelsteen, I; van den Ouweland, A; Peterlongo, P; Phuah, SY; Pylkäs, K; Rowley, SM; Sangrajrang, S; Schmutzler, RK; Shen, C-Y; Shu, X-O; Southey, MC; Surowy, H; Swerdlow, A; Teo, SH; Tollenaar, RAEM; Tomlinson, I; Torres, D; Truong, T; Vachon, C; Verhoef, S; Wong-Brown, M; Zheng, W; Zheng, Y; Nevanlinna, H; Scott, RJ; Andrulis, IL; Wu, AH; Hopper, JL; Couch, FJ; Winqvist, R; Burwinkel, B; Sawyer, EJ; Schmidt, MK; Rudolph, A; Dörk, T; Brauch, H; Hamann, U; Neuhausen, SL; Milne, RL; Fletcher, O; Pharoah, PDP; Campbell, IG; Dunning, AM; Le Calvez-Kelm, F; Goldgar, DE; Tavtigian, SV; Chenevix-Trench, G (2016-05)
      BACKGROUND:BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation (FANC) group family of DNA repair proteins. Biallelic mutations in BRIP1 are responsible for FANC group J, ...
    • Noise-Corrected, Exponentially Weighted, Diffusion-Weighted MRI (niceDWI) Improves Image Signal Uniformity in Whole-Body Imaging of Metastatic Prostate Cancer. 

      Blackledge, MD; Tunariu, N; Zungi, F; Holbrey, R; Orton, MR; Ribeiro, A; Hughes, JC; Scurr, ED; Collins, DJ; Leach, MO; Koh, D-M (2020-01)
      Purpose: To characterize the voxel-wise uncertainties of Apparent Diffusion Coefficient (ADC) estimation from whole-body diffusion-weighted imaging (WBDWI). This enables the calculation of a new parametric map based on ...
    • NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL 

      Larrayoz, M; Rose-Zerilli, MJ; Parker, H; Blakemore, SJ; Forster, J; Davis, Z; Steele, AJ; Else, M; Catovsky, D; Oscier, DG; Strefford, JC (2016-06)
    • Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. 

      Hahne, JC; Valeri, N (2018-01)
      Non-coding RNAs are important regulators of gene expression and transcription. It is well established that impaired non-coding RNA expression especially the one of long non-coding RNAs and microRNAs is involved in a number ...
    • The non-coding variant rs1800734 enhances DCLK3 expression through long-range interaction and promotes colorectal cancer progression. 

      Liu, NQ; Ter Huurne, M; Nguyen, LN; Peng, T; Wang, S-Y; Studd, JB; Joshi, O; Ongen, H; Bramsen, JB; Yan, J; Andersen, CL; Taipale, J; Dermitzakis, ET; Houlston, RS; Hubner, NC; Stunnenberg, HG (2017-02-14)
      Genome-wide association studies have identified a great number of non-coding risk variants for colorectal cancer (CRC). To date, the majority of these variants have not been functionally studied. Identification of ...
    • Non-coplanar trajectories to improve organ at risk sparing in volumetric modulated arc therapy for primary brain tumors. 

      Smyth, G; Evans, PM; Bamber, JC; Mandeville, HC; Welsh, LC; Saran, FH; Bedford, JL (2016-10)
      To evaluate non-coplanar volumetric modulated arc radiotherapy (VMAT) trajectories for organ at risk (OAR) sparing in primary brain tumor radiotherapy.Fifteen patients were planned using coplanar VMAT and compared against ...
    • Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model. 

      Hill, DK; Heindl, A; Zormpas-Petridis, K; Collins, DJ; Euceda, LR; Rodrigues, DN; Moestue, SA; Jamin, Y; Koh, D-M; Yuan, Y; Bathen, TF; Leach, MO; Blackledge, MD (2017-01)
      Diffusion-weighted magnetic resonance imaging (DWI) enables non-invasive, quantitative staging of prostate cancer via measurement of the apparent diffusion coefficient (ADC) of water within tissues. In cancer, more advanced ...
    • Non-Mono-Exponential Analysis of Diffusion-Weighted Imaging for Treatment Monitoring in Prostate Cancer Bone Metastases. 

      Reischauer, C; Patzwahl, R; Koh, D-M; Froehlich, JM; Gutzeit, A (2017-07-19)
      Diffusion-weighted imaging quantified using the mono-exponential model has shown great promise for monitoring treatment response in prostate cancer bone metastases. The aim of this prospective study is to evaluate whether ...
    • Noncoding RNA in Cholangiocarcinoma. 

      Salati, M; Braconi, C (2019-02)
      Cholangiocarcinomas (CCAs) are tumors with a dismal prognosis. Early diagnosis is a key challenge because of the lack of specific symptoms, and the curability rate is low due to the difficulty in achieving a radical resection ...
    • Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know? 

      Previdi, MC; Carotenuto, P; Zito, D; Pandolfo, R; Braconi, C (2017-02)
      Pancreatic cancer is an aggressive cancer of the digestive system, which is becoming a serious health problem worldwide. Overall survival for patients with pancreatic cancer is poor, mainly due to a lack of biomarkers to ...